

Review of: "Risk of death derived from Hazard Ratio should not be communicated as Relative Risk reductions for death in cancer clinical trials. Intentional or inadvertent?"

Cristina Donfrancesco¹

¹ Sapienza University of Rome

Potential competing interests: No potential competing interests to declare.

The review is well written and provides detailed information regarding a new way to approach studies results. I found the explications and the methods section well done, the curves gives an immediate clarification of what they mean.

Regarding the object of the study, the approach is novel and particularly meaningful because the topic act as a “bridge” between statistical analysis and cancer patient's quality of life and their life expectancy. In this way it is interesting and innovative. This is the strength of the study and its novel side, aside from other considerations.